STOCK TITAN

Quest Diagnostics Inc - DGX STOCK NEWS

Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.

Quest Diagnostics Incorporated (DGX) provides essential diagnostic insights and testing services across the U.S. healthcare system. This news hub aggregates official press releases, financial updates, and strategic developments from one of America's leading clinical laboratory networks.

Investors and healthcare professionals will find timely updates on earnings reports, partnership announcements, and technological advancements in diagnostic testing. Our curated news feed includes regulatory milestones, service expansions, and innovations leveraging DGX's vast clinical database.

Key updates cover emerging trends in precision diagnostics, laboratory network growth, and healthcare collaborations. Users can track the company's progress in cancer detection, genomic testing, and data-driven health solutions through verified primary sources.

Bookmark this page for direct access to DGX's latest financial performance data, leadership changes, and operational developments. Visit regularly to stay informed about how Quest Diagnostics continues shaping diagnostic medicine through clinical excellence and strategic initiatives.

Rhea-AI Summary
Quest Diagnostics Incorporated (NYSE: DGX) to Present at J.P. Morgan Healthcare Conference, Offering Insight into Company Strategy and Market Trends
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences
-
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) announced the appointment of Yuri A. Fesko, M.D., as senior vice president and chief medical officer. Dr. Fesko, a seasoned healthcare executive, will oversee medical affairs, clinical development, and health plan policy support for new services and care delivery models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) and Scipher Medicine Announce Collaboration to Expand Precision Medicine for Rheumatoid Arthritis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) unveils new confirmatory testing service for novel psychoactive substances (NPS) with 88 compounds, including xylazine and acetyl fentanyl. The Health Trends® report found xylazine in 1 in 12 specimens tested, indicating a rising polysubstance crisis in America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics (DGX) Receives 100% Score on Corporate Equality Index for Seventh Consecutive Year
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
Rhea-AI Summary
Haystack Oncology (DGX) collaborates with Rutgers Cancer Institute of New Jersey to use Haystack MRD™ technology for a clinical trial on early-stage triple-negative breast cancer patients. The technology aims to provide molecular insights and evaluate therapeutic response, potentially leading to better outcomes for patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
Rhea-AI Summary
Quest Diagnostics (DGX) aims to implement a waste-to-energy strategy, reduce medical waste, and improve water stewardship by 2025. The company has already made significant progress in waste reduction, plastic waste reduction, paper waste reduction, and water use efficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.23%
Tags
none
-
Rhea-AI Summary
Quest Diagnostics (DGX) collaborates with Community Health Centers to address current healthcare needs among underserved populations. The company surveyed FQHC leaders and found that staffing, nontraditional care services, and operational/financial concerns are the main challenges. Quest aims to support health centers in providing comprehensive care by breaking down affordability barriers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
-
Rhea-AI Summary
UDX (Universal DX) announces a strategic collaboration with Quest Diagnostics (DGX) and the initial closing of its series B financing of approximately $70 million. The collaboration aims to improve colorectal cancer screening in the United States by combining UDX's Signal-C® technology with Quest's expertise and national scale. The company plans to pursue FDA premarket approval for its colorectal cancer screening blood test and enroll patients in a 15,000-patient study. The test has shown 93% sensitivity for colorectal cancer detection and 54% sensitivity for detection of precancerous lesions at 92% specificity overall.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) has been awarded a multi-year contract by the CDC to assess the burden of hepatitis C virus (HCV) in the United States. The company will provide research consulting, laboratory testing, and data analytics services to generate diagnostics insights supporting population health strategy for hepatitis C.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags
none
Quest Diagnostics Inc

NYSE:DGX

DGX Rankings

DGX Stock Data

18.18B
111.14M
0.44%
93.75%
2.31%
Diagnostics & Research
Services-medical Laboratories
Link
United States
SECAUCUS